ReachRxResearch
Home
Research
Sign Up
Site-Specific Treatment and Remission Patterns in Multisite Mucous Membrane Pemphigoid
Back to Research Hub
  1. Home
  2. Research Hub
  3. Site-Specific Treatment and Remission Pa…

Site-Specific Treatment and Remission Patterns in Multisite Mucous Membrane Pemphigoid

JAMA Dermatology·October 28
DermatologyPractice changingMucous Membrane PemphigoidRetrospective Cohort StudyAlkylating AgentAnti-CD20 Monoclonal AntibodyJAK InhibitorOlder AdultRituxanCyclophosphamideRituximab

Summary

View source

What was studied

This retrospective cohort study (2013–2025, n=77) evaluated multisite complete remission (mCR) and site-specific treatment response patterns in patients with immunopathology-confirmed mucous membrane pemphigoid (MMP) involving ≥2 anatomic sites, with ≥12 months of follow-up.

Key findings

Only 35 of 77 patients (45%) achieved mCR, taking a median of 32 months; while 64 (83%) reached complete remission at ≥1 site, persistent oral and ocular disease most often blocked global control. Relapses after site-level CR occurred in 44%, most commonly at oral (64%) and ocular (50%) mucosa. Rituximab-based regimens and JAK inhibitor therapy showed high improvement rates; serious adverse events were most frequent with cyclophosphamide monotherapy and JAK inhibitors.

Study limitations

Single tertiary referral center limits generalizability to less complex or community-based MMP populations. Retrospective design introduces selection and documentation bias. No head-to-head controlled comparisons between treatment regimens were performed.

Clinical implications

Clinicians should not equate site-level remission with disease control in multisite MMP—nearly half of patients never achieve simultaneous remission across all sites, and relapses are common especially at oral and ocular mucosa. Standardized multisite remission endpoints should be incorporated into future trials and clinical monitoring plans.

Caveats

  • 88% of the cohort had high-risk multisite MMP from a single tertiary referral center; findings may not reflect disease course in community or lower-risk settings
  • JAK inhibitor serious adverse events are noted but the specific agents and dosing are not detailed in the abstract, limiting safety interpretation
  • Median follow-up or overall study duration per patient is not explicitly reported, which may affect assessment of long-term remission and relapse rates

Related Questions

Explore related topics

What are the best treatment options for ocular mucous membrane pemphigoid?How does rituximab compare to cyclophosphamide in autoimmune blistering diseases?JAK inhibitor safety profile in autoimmune mucosal diseases

Publication Details

Year
2026
Journal
JAMA Dermatology
Sample Size
n=77
Source
View article
Keep scrolling
More content below.
Up Next